MX2023000760A - Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso. - Google Patents
Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso.Info
- Publication number
- MX2023000760A MX2023000760A MX2023000760A MX2023000760A MX2023000760A MX 2023000760 A MX2023000760 A MX 2023000760A MX 2023000760 A MX2023000760 A MX 2023000760A MX 2023000760 A MX2023000760 A MX 2023000760A MX 2023000760 A MX2023000760 A MX 2023000760A
- Authority
- MX
- Mexico
- Prior art keywords
- telomerase inhibitor
- subcutaneous
- methods
- inhibitor compositions
- same
- Prior art date
Links
- 229940123582 Telomerase inhibitor Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000003277 telomerase inhibitor Substances 0.000 title abstract 4
- 238000007920 subcutaneous administration Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 125000003473 lipid group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01036—Hyaluronoglucuronidase (3.2.1.36)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Los aspectos de la descripción incluyen composiciones inhibidoras de la telomerasa formuladas para administración subcutánea. Las composiciones de acuerdo con determinadas modalidades incluyen una enzima hialuronidasa y un inhibidor de telomerasa que tiene un oligonucleótido y un resto lipídico unido al extremo 5' y/o 3' del oligonucleótido. También se describen métodos para administrar por vía subcutánea las composiciones inhibidoras de la telomerasa, tales como en el tratamiento de una neoplasia. También se proporcionan kits que tienen o no tienen un inyector subcutáneo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063053455P | 2020-07-17 | 2020-07-17 | |
US202063128708P | 2020-12-21 | 2020-12-21 | |
PCT/US2021/041755 WO2022015935A2 (en) | 2020-07-17 | 2021-07-15 | Subcutaneous telomerase inhibitor compositions and methods for using same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000760A true MX2023000760A (es) | 2023-02-13 |
Family
ID=79556008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000760A MX2023000760A (es) | 2020-07-17 | 2021-07-15 | Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220168403A1 (es) |
EP (1) | EP4182031A2 (es) |
JP (1) | JP2023534295A (es) |
KR (1) | KR20230041707A (es) |
CN (1) | CN115776909A (es) |
AU (1) | AU2021309963A1 (es) |
CA (1) | CA3181682A1 (es) |
IL (1) | IL299205A (es) |
MX (1) | MX2023000760A (es) |
TW (1) | TW202218668A (es) |
WO (1) | WO2022015935A2 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7125858B2 (en) * | 1999-12-28 | 2006-10-24 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
EP2405015B1 (en) * | 2003-03-05 | 2016-01-06 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
EP2771300B1 (en) * | 2011-10-25 | 2017-12-20 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
PT3130347T (pt) * | 2011-12-30 | 2019-12-10 | Halozyme Inc | Variantes de polipéptidos de ph20, suas formulações e utilizações |
US9375485B2 (en) * | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
UA117141C2 (uk) * | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
PT3065828T (pt) * | 2013-11-06 | 2019-04-01 | Mayo Found Medical Education & Res | Métodos e materiais para tratar malignidades hematológicas |
-
2021
- 2021-07-15 CN CN202180048456.3A patent/CN115776909A/zh active Pending
- 2021-07-15 MX MX2023000760A patent/MX2023000760A/es unknown
- 2021-07-15 IL IL299205A patent/IL299205A/en unknown
- 2021-07-15 KR KR1020237002572A patent/KR20230041707A/ko unknown
- 2021-07-15 WO PCT/US2021/041755 patent/WO2022015935A2/en active Application Filing
- 2021-07-15 JP JP2023503097A patent/JP2023534295A/ja active Pending
- 2021-07-15 US US17/376,517 patent/US20220168403A1/en active Pending
- 2021-07-15 EP EP21842404.2A patent/EP4182031A2/en active Pending
- 2021-07-15 CA CA3181682A patent/CA3181682A1/en active Pending
- 2021-07-15 AU AU2021309963A patent/AU2021309963A1/en active Pending
- 2021-07-16 TW TW110126320A patent/TW202218668A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20220168403A1 (en) | 2022-06-02 |
TW202218668A (zh) | 2022-05-16 |
CN115776909A (zh) | 2023-03-10 |
EP4182031A2 (en) | 2023-05-24 |
WO2022015935A2 (en) | 2022-01-20 |
AU2021309963A1 (en) | 2023-02-02 |
JP2023534295A (ja) | 2023-08-08 |
CA3181682A1 (en) | 2022-01-20 |
IL299205A (en) | 2023-02-01 |
KR20230041707A (ko) | 2023-03-24 |
WO2022015935A3 (en) | 2022-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA85055C2 (ru) | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний | |
CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
WO2000063364A3 (en) | Methods and compositions for inhibiting the function of polynucleotide sequences | |
BR112022025583A2 (pt) | Conjugado de molécula de ligação à superfície celular e análogo de camptotecina, composto conjugável, célula de tumor, composição farmacêutica, agente quimioterapêutico, e, agentes sinergísticos | |
TW200609227A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
AU2003211149A1 (en) | Antimicrobial therapeutic compositions and methods of use | |
MX339658B (es) | Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa. | |
MX2021011948A (es) | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. | |
MX2008000838A (es) | Composiciones y metodos para tratar infeccion bacteriana gram positiva en un sujeto mamifero. | |
WO2022217123A3 (en) | Combination therapies with cbl-b inhibitor compounds | |
MX2023000760A (es) | Composiciones subcutaneas del inhibidor de la telomerasa y metodos para su uso. | |
WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
WO2019139956A3 (en) | Prevention and treatment of organ fibrosis | |
NZ601232A (en) | Tissue targeted antigenic activation of the immune response to treat cancers | |
WO2021216687A9 (en) | Peptides for the treatment of covid-19 | |
PL378713A1 (pl) | Kompozycje przeciwpierwotniakowe, zawierające diklazuryl | |
WO2022118016A3 (en) | Enzyme inhibitors | |
EP1663280A4 (en) | METHOD FOR IMPROVING HEMATOPOIESE | |
EP1610814B8 (en) | Therapeutic composition for autoimmune conditions | |
CR20230258A (es) | Compuestos y composiciones de moléculas pequeñas | |
Gaetani et al. | Effect of 5-fluorouracil on hepatic induced increase of tryptophan-pyrrolase | |
MX2022012982A (es) | Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis. | |
WO2023172497A3 (en) | Compounds, compositions, and methods for treating, ameliorating, and/or preventing cocaine use disorder | |
ATE439857T1 (de) | Lipoglykan zusammensetzungen und methoden zur behandlung von parasitischen infektionen | |
YU30602A (sh) | Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima |